Dyadic partners with BRIG BIO, Strive Nutrition to develop precision-fermented alpha-lactalbumin

By Public Technologies
  • Dyadic International entered a collaboration with BRIG BIO and Strive Nutrition to develop and commercialize precision-fermented bovine alpha-lactalbumin for U.S. nutrition markets.
  • The partners will use the Dapibus production platform to develop the protein for Strive’s FREEMILK platform and other nutrition products.
  • Initial commercial availability is targeted at more than 10 metric tonnes, subject to successful development, regulatory readiness, quality qualification and definitive agreements.
  • Completion of the self-affirmed GRAS process is targeted for early 2028, ahead of initial commercial availability.
  • Longer-term production is targeted at more than 200 metric tonnes annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100730PRIMZONEFULLFEED9874271) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.